Another thing stated is the company is cash flow neutral, and is very close to profitability. The company is profitable on the Tollovid product line and can reduce margin with the 50% off sale and still be profitable.

The valuation of Tollovir in the hospitalized setting is very high and will be used to obtain additional funding that is non-dilutive and will allow the 2020 financing that is currently impacting share price to be paid off.

Another great presentation. Gerald seems very confident and excited about what lies ahead. New opportunities are opening up.